Literature DB >> 9863907

Masculinizing sclerosing stromal cell tumor in pregnancy: report of a case and review of the literature.

L R Duska1, C Flynn, A Goodman.   

Abstract

PURPOSE: To report a case of sclerosing stromal cell tumor of the ovary in pregnancy and to review the literature of this rare ovarian tumor.
METHODS: The patient's office record and hospital record were reviewed. Gross and microscopic pathology were reviewed by one gynecologic pathologist. A Medline literature search and literature review were performed.
RESULTS: Over eighty cases of sclerosing stromal cell tumor of the ovary have been reported in the literature since the definition of this pathologic condition in 1973. Only five cases have been reported during pregnancy and only two of these resulted in maternal virilization. This report describes severe maternal virilization with birth of a non-virilized female infant.
CONCLUSION: Sclerosing stromal cell tumor of the ovary can result in severe virilization via androgen production. Surgery with removal of the involved ovary is required for diagnosis and cure. Prognosis is excellent.

Entities:  

Mesh:

Year:  1998        PMID: 9863907

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  3 in total

1.  Different Presentations of Five Rare Cases of Sclerosing Stromal Tumor of the Ovary.

Authors:  Mozhdeh Momtahan; Mojgan Akbarzadeh-Jahromi; Fateme Sadat Najib; Niloofar Namazi
Journal:  Indian J Surg Oncol       Date:  2018-05-19

2.  Endocrine pathology of the ovary : in tribute to Robert E Scully, MD.

Authors:  Esther Oliva; Robert H Young
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

Review 3.  Ovarian carcinoma associated with pregnancy: a clinicopathologic analysis of 23 cases and review of the literature.

Authors:  Nadereh Behtash; Mojgan Karimi Zarchi; Mitra Modares Gilani; Fatemeh Ghaemmaghami; Azamsadat Mousavi; Fahimeh Ghotbizadeh
Journal:  BMC Pregnancy Childbirth       Date:  2008-01-20       Impact factor: 3.007

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.